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Background: Low-molecular-weight heparins (LMWH) are the most commonly used anticoagulant during
pregnancy for prevention or treatment of VTE. However, the size of the associated risk of postpartum hae-
morrhage (PPH) is unknown.
Objective: To assess the bleeding risk of high dose LMWH, also in relation to time between last dose LMWH
and delivery.
Material and methods: From 1999 to 2009, we followed 88 pregnant women who were started on therapeutic
anticoagulation. Controls were pregnant women without LMWH, matched 1:4 for parity, mode of delivery,
age, gestational age and delivery date. PPH was deﬁned as >500 ml blood loss for vaginal delivery (severe
PPH in vaginal delivery as >1000 ml) and >1000 ml for cesarean section (CS). Women were divided into
subgroups by the interval between last dose of anticoagulation and delivery (b12, 12-24 hrs, >24 hrs).
Results: Risk of PPH after vaginal delivery was 30% and 18% for LMWH-users and non-users, respectively (OR
1.9, 95%CI 1.1-3.5). Risk of severe PPH after vaginal delivery was not different (5.6 vs 5.0%; OR 1.1; 0.4-3.6).
Risk of PPH after CS was 12% in LMWH-users and 4% in non-users (OR 2.9; 0.5-19.4). Both events of LMWH-
users occurred after emergency CS. The risk of PPH associated with delivery within 24 hours after last dose of
LMWH was 1.2 fold higher (95%CI 0.4-3.6) compared to a larger interval.
Conclusion: High dose LMWH carries an increased risk of more than 500 mL blood loss after vaginal delivery.
However, this results not in more clinical relevant severe PPHs. The interval between last dose of LMWH and
delivery does not inﬂuence the risk of PPH.© 2012 Elsevier Ltd. All rights reserved.Introduction
In the general population, 0.5 in 1000 pregnancies [1] is compli-
cated by a venous thrombo-embolism (VTE), with a predominance
in the puerperium.[2,3] In women with a previous episode of VTE,
the risk of recurrence during pregnancy ranges from 2.4-6.2%.[4,5]
For these women, with either a current VTE or a high risk of recurrent
VTE, low molecular weight heparin (LMWH) is the most commonly
used anticoagulant during pregnancy. The optimal dosage of throm-
boprophylaxis in women with an increased risk of VTE during preg-
nancy and puerperium is not established.[6] In our hospital, allnd Haemostasis, Berlin, Febru-
logy, Division of Haemostasis
, Hanzeplein 1, 9713 GZ Gro-
31 50 3611790.
rights reserved.pregnant women with an indication for thromboprophylaxis received
a high dose intended as a therapeutic dosage of LMWH during preg-
nancy and the puerperium.
Usage of LMWH during pregnancy may be associated with an in-
creased risk of blood loss or postpartum hemorrhage (PPH), a com-
mon complication of childbirth and a leading cause of maternal
morbidity and mortality. Few studies assessed the risk of PPH associ-
ated with usage of LMWH [7–14], but most studies are retrospective
cohort studies, without a control group and describing only a small
number of women on therapeutic dosage LMWH.
Further, current guidelines recommend discontinuing LMWH
at least 24 hours before labor [6], although no data are available
whether this inﬂuences the risk of PPH. This is challenging as
labor may start unplanned.
We performed a retrospective cohort study in our hospital to
evaluate our treatment protocol to assess the bleeding risk with
high dose therapeutic dosage LMWH during delivery compared to






Median age at pregnancy, years 30 30
Median gestational age at delivery, weeks 39 0/7 39 4/7
Median birthweight, gram 3360 3360
Aspirin use 0 0
Indication for anticoagulation, n(%)
History of VTE 64 (73)
Recurrent fetal loss 5 (6)
Asymptomatic thrombophilic defects‡ 14 (16)
VTE in current pregnancy 5 (6)
Mode of delivery, n
Vaginal, normal delivery 65 260
Vaginal, assisted 6 24
Cesarean section, primary 8 32
Cesarean section, secondary 9 36
‡ Antithrombin, protein C and protein S deﬁciency.
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Patients
This is a retrospective cohort study, including as cases consecutive
womenwho started with a therapeutic dosage LMWH during pregnan-
cy at our hospital between 1999 and 2009. Thesewomenwere followed
prospectively during pregnancy in combined obstetric/ coagulation
clinic and seen by a thrombosis specialist every 2 months until
6 weeks post-partum. Indications for anticoagulation were a history of
idiopathic, provoked or pregnancy related VTE, recurrent fetal loss or
asymptomatic thrombophilic defects (protein C, S or AT deﬁciency).
For a given woman, we included only the ﬁrst ongoing pregnancy in
which she used anticoagulation, to avoid selection bias. Pregnancies
with early fetal loss were not included. Detailed information on epi-
sodes of VTE, external risk factors for thrombosis, obstetric history, an-
ticoagulant treatment and delivery was collected using a standardised
questionnaire. Data on labor was collected retrospectively by reviewing
medical records. National legislation and the ethical committee of our
institution approve this type of studies without the need for review of
the protocol.
Treatment Protocol
Women were started on a therapeutic dosage of nadroparin once
daily in early pregnancy with bodyweight adjusted therapeutic dos-
age (175 anti-Xa IU kg−1 day−1), as soon as a pregnancy test was
positive or when a VTE occurred during pregnancy. All women were
followed by a thrombosis specialist every 2 months until 6 weeks
post-partum. Anti-fXa levels were not routinely monitored and
doses of LMWH were not adjusted for increasing bodyweight or in-
creasing renal clearance. If hypersensitivity skin reactions developed,
we switched to another preparation, fondaparinux, danaparoid or
acenocoumerol. The women had no planned induction of labor with
withholding of anticoagulation, but all women switched to divided
(twice daily) dosing of their LMWH in the 37th week to minimize
the bleeding risk. Women who used acenocoumerol switched to a
twice daily dosing LMWH in the 37th week. Second, LMWH or anoth-
er preparation was stopped at the start of spontaneous or induced
labor and restarted 4–8 hours after delivery (when blood loss was
normal) and stopped six weeks postpartum. Women with a current
VTE during pregnancy were treated for six months, but at least until
six weeks postpartum.
Controls
Controls were women who delivered in our hospital and did not
use LMWH or another anticoagulant during pregnancy. LMWH users
were matched 1:4 to controls (non-users) by random electronic se-
lection for parity, mode of delivery, age, gestational age, and date of
delivery (+/−2 years). Exclusion criteria for the controls were a his-
tory of VTE or PPH.
Deﬁnitions
The amount of blood loss was a visual estimation. According to the
WHO guidelines, we deﬁned >500 ml as deﬁnition of PPH for vaginal
delivery and >1000 ml for a cesarean section. Severe PPH was de-
ﬁned as >1000 ml for a vaginal delivery. Primary and secondary
PPH were deﬁned as a bleeding within 24 hours after delivery and
after 24 hours, respectively [15].
Statistical Analysis
Continuous variables were expressed as mean or median values and
standard deviations or ranges depending on normality, categorical dataas counts and percentages. Differences between groups were evaluated
by the student t test or Mann–Whitney U test, depending on the normal-
ity of data for continuous data, and by Fisher exact test for categorical
data. A two-tailed p-value of less than 0.05 was considered statistically
signiﬁcant. Women were divided into subgroups by the various intervals
between last dose of LMWH and delivery (b12 hrs, 12–24 hrs, >24 hrs).
Logistic regression was performed for calculating odds ratios for PPH in
users and non-users and in relation to timing of last injection of LMWH
with adjustment for known risk factors for PPH, such as age, parity and
birth weight >4000 gram. Statistical analyses were performed using
PASW version 18.0 (IBM SPSS, Chicago, Illinois, United States).
Results
We followed 143 pregnancies in 88 women. We included 88 ﬁrst
pregnancies in which women used full dose anticoagulation. Baseline
characteristics are shown in Table 1. Median age was 30 yrs (range
20–43 yrs), 66% was nulliparous. All women started with nadroparin.
Sixty-eight percent (n=60) used LMWH during the whole pregnan-
cy, 17 (19%) women switched to acenocoumarol between 16 and
36 weeks, 9 (10%) switched to fondaparinux, 2 (2%) switched to
danaparoid and one woman switched to unfractionated heparin dur-
ing labor. The reason for switching was mostly hypersensitivity skin
reactions or (for VKA) the wish to avoid injections. All women used
a dosage of anticoagulation intended as therapeutic during
pregnancy.
Modes of deliveries were vaginal in 81% and cesarean section (CS)
in 19% (9% elective, 10% emergency). Labor was induced in 26 of 88
women: this was in 17/71 (24%) women who had a vaginal delivery,
1/9 (11%) of the women who had an emergency CS and 8 women
who had a primary CS. Median gestational age was 39 0/7 weeks
(28 3/7-42 3/7). One late fetal loss in the 30th week due to abruptio
placenta was reported in this cohort. In total, 3 pregnancies were
complicated by preeclampsia and 3 by HELLP syndrome.
Bleeding Complications During Pregnancy
Of the 88 patients, 5 (6%) had vaginal blood loss during pregnancy
without gynecological abnormalities. All these women used LMWH.
One patient had epistaxis around the 20th week and 10% had
hematoma due to injection of the LMWH. No other bleeding episodes
were reported.
Bleeding Complications During and After Delivery
Risk of PPH after vaginal delivery was 30% vs. 18% for LMWH-users
and non-users, respectively (OR 1.9; 95%CI 1.1-3.5; p=0.029). Risk of
Fig. 1. Blood loss after vaginal delivery in users vs non-users.
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both groups (5.6 vs 5.0%; OR 1.1; 95%CI 0.4-3.6; p=0.83). Of the
LMWH-users who had a severe PPH after vaginal delivery (4/71), 2
had uterine atony, one had retained placenta and one had a PPH after
vacuum extraction due to uterine atony. Risk of PPH inwomenwho de-
livered by CS was 12% (2/17) in LMWH-users and 4% (3/67) in non-
users (OR 2.9; 95%CI 0.5-19.4; p=0.26). Both events in LMWH-users
occurred after emergency CS, but both had their last injection of
LMWH>12 hours before the CS. See also Table 2. The reasons for emer-
gency CS were fetal distress (n=5), prolonged 2nd stage of labor
(n=1) and a prolonged 1st labor. (n=3). None of the women with a
pregnancy complicated by HELLP-syndrome or pre-eclampsia experi-
enced a severe PPH.
Of the women who used danaparoid (n=2) and unfractionated
heparin (n=1) during delivery, none experienced a PPH. Of the
women who used fondaparinux during delivery (n=9), one experi-
enced a PPH, but she had her last injection 48 hours before.
The amount of blood loss after vaginal delivery is presented in Fig. 1,
showing an increased percentage of women with PPH (blood loss
500 ml ormore), but not of severe PPH (over 1000 ml). Of note, theme-
dian blood losswas comparable after primary (350 vs 325 ml; p=0.79)
and emergency CS (425 vs 400 ml; p=0.29) in users vs non-users,
respectively.
In total, 8% (2/26) of LMWH users vs 11% (8/73) of the non-users
who experienced a PPH, needed red blood cell (RBC) transfusion
(p=0.46).
Finally, one woman who used LMWH experienced a secondary
PPH (>24 hrs).
Timing of Last Injection LMWH and Risk of Bleeding
Of the 88 women with anticoagulation during ﬁrst pregnancy
(LMWH users), 10 women delivered within 12 hours after the last
injection of LMWH, 37 women within 12–24 hours and 26 women
after 24 hours. In 15 women (17%), the timing was unknown. The
time between last injection and delivery of the women who deliv-
ered within 12 hours ranged from 5 to 11 hours, with a median of
6 hours. Median blood loss in women who delivered before 12 hours
after last dose of LMWH was comparable to 12–24 hours and after 24
hours (275 vs 350 vs 325 ml; p=0.30). Risk of a PPH after vaginal and
CS delivery was 30%, 38% and 27% for intervals of b12, 12–24 and >24
hours, respectively (p=0.36). Risk of a severe PPH was 0%, 11% and 4%Table 2









500 ml 29.5 23.6 0.08 1.6 (0.9-2.7)
1000 ml 6.8 4.8 0.46 1.4 (0.5-3.8)
Vaginal delivery (overall)
500 ml 29.6 17.8 0.029 1.9 (1.1-3.5)
1000 ml 5.6 5.0 0.83 1.1 (0.4-3.6)
Vaginal delivery (spontaneous)
500 ml 26.1 15.8 0.058 1.9 (1.0-3.6)
1000 ml 4.6 3.8 0.79 1.2 (0.3-4.5)
Vaginal delivery (assisted)
500 ml 66.7 37.5 0.21 3.3 (0.5-22.0)
1000 ml 16.7 16.6 1.0 1.0 (0.1-11.1)
Cesarean section (overall)
1000 ml 11.7 4.4 0.26 2.9 (0.5-19.4)
Cesarean section (primary)
1000 ml 0 6.3 0.45
Cesarean section (emergency)
1000 ml 22.2 2.8 0.06 11.3 (1.0-145.5)for intervals of b12, 12–24 and >24 hours, respectively (p=0.58). Over-
all, the risk of PPH within 24 hours after the last injection of LMWH did
not signiﬁcantly differ from the risk in women who delivered more
than 24 hours after the last injection (OR 1.4; 95% CI 0.5-3.9; p=0.56).
After adjustment for age, birthweight >4000 gram and parity, OR was
1.2 (95% CI 0.4-3.6; p=0.73). See for detailed data Table 3. In 17% of the
women (n=15) we had missing data about the timing of last injection
of LMWH, but their median blood loss was comparable with the
women who delivered within and after 24 hours (300 vs 350 vs
249 ml; p=0.21).
Of the women who had a planned induction of labor, 50% deliv-
ered within 24 hours after the last dose of LMWH and of the
women who had spontaneous onset of labor 58% delivered within
24 hours. After adjustment for parity, age and birthweight >4000
gram, LMWH-users who had a spontaneous onset of labor had a 1.9
fold increased risk for PPH compared to women who had a planned
induction of labor (95% CI 0.6-5.8; p=0.29).Thrombo-embolic Complications
No recurrent VTE was reported in the women who used therapeu-
tic dosage LMWH because of a history of VTE. Five women had a cur-
rent VTE during the pregnancy, one woman had a recurrent VTE in
the 8th week and one woman in the 34th week of pregnancy while
they had not yet started their thromboprophylaxis. Three patients
had a ﬁrst VTE in 8th, 10th and 37th week of pregnancy and started
with therapeutic dosage of LMWH.Table 3
Risk of PPH based on interval between last injection of LMWH and delivery.
b24 hrs >24 hrs OR (95%CI) OR (95%CI)‡ p ‡
Overall
MBL, ml 300 350
PPH, % 34.7 28.0 1.4 (0.5-3.9) 1.2 (0.4-3.6) 0.73
Vaginal delivery
MBL, ml 300 300
PPH (>500 ml), % 35.0 26.3 1.5 (0.5-5.1) 1.3 (0.4-4.8) 0.68
Cesarean section
MBL, ml 400 400
PPH (>1000 ml), % 11.1 16.7 0.7 (0.03-12.4) 0.4 (0.1-21.4) 0.67
‡ adjusted for age, parity and birthweight >4000 gram; MBL: median blood loss.
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In this study, we analysed the bleeding risk of high dose LMWH
during pregnancy and the puerperium in 88 pregnancies. We showed
that women who used LMWH had a 1.9-fold increased risk for PPH,
but this did not result in more RBC transfusions. We observed no in-
creased risk for a severe PPH after vaginal delivery. The PPH risk
was not increased in women who delivered within 24 hours after
the last injection of LMWH as compared to women who delivered
more than 24 hours after the last dose LMWH.
Overall, we reported 30% PPH (>500 mL) and 6% severe PPH after
vaginal deliveries in womenwho used LMWH. There are a few studies
who also reported the bleeding risk of high dose or therapeutic dos-
age of LMWH.[7,10,13,16] Kominiarek et al. [7] reported no increased
bleeding risk in a case–control study of 49 women using LMWH dur-
ing pregnancy. Sixty-seven percent used a therapeutic dosage of
LMWH, but they did not analyse the risk of therapeutic dosages sep-
arately. Furthermore 70% had more than 24 hours between last dose
of LMWH and delivery. Voke et al.[13] reported a 5% incidence of pri-
mary PPH (>500 mL) in 126 women with a VTE during the current
pregnancy followed by therapeutic dosage LMWH, but there was no
control-group. Rowan et al.[10] described no bleeding complications
in 32 pregnancies with therapeutic dosage of LMWH, but 26 of
these women had a planned induction of labor. Lepercq et al.[16] de-
scribed 624 pregnancies of which 49 women used a therapeutic dos-
age of enoxaparin. They found no increased bleeding risk, but did not
analyse the pregnancies with therapeutic dosage separately.
We observed 18% PPH and 5% severe PPH in our matched controls
after vaginal delivery. This is comparable with ﬁndings of a
population-based cohort analysed in the Netherlands, which showed
a risk for PPH (>500 ml) and severe PPH (>1000 ml) of 19% and 4.2%
after vaginal delivery, respectively.[15] There is no single, satisfactory
deﬁnition for PPH worldwide. In the Netherlands a PPH is deﬁned as
>1000 ml blood loss for a vaginal delivery and a cesarean section. Be-
cause different countries and the WHO deﬁne PPH as more than
500 ml blood loss after vaginal delivery, we also used these cut-off
values for the analysis. We observed no increased risk for a severe
PPH after a vaginal delivery. Moreover, Fig. 1 shows that the distribu-
tion of the amount of blood loss lies mainly below 1000 mL. This
amount of blood loss is usually not clinical relevant, because this
leads mostly not to a RBC transfusion and an extension of the hospital
stay.
In our cohort women started with a therapeutic weight-adjusted
once daily dosage of LMWH in the beginning of their pregnancy
until 37 weeks of gestation. During pregnancy LMWH requirements
may alter because the glomerular ﬁltration rate increases in the 2nd
trimester and the volume of distribution of LMWH changes. Given
these physiologic changes, Crowther et al.[17] suggested that the dos-
age of LMWH should be increased in proportion to the change in
body-weight. However, adjustment of the dose of LMWH according
to anti-fXa levels and increasing body-weight is controversial. Some
small studies showed that periodic (every 1–3 months) dose-
adjustment to maintain therapeutic anti-fXa levels is essential.[18,19]
However, other studies demonstrated that only a few women require
dose adjustment when therapeutic doses of LMWH are used.[20–22]
Therefore, in the absence of large studies with clinical end-points of
optimal dosage during pregnancy we decided to not routinely moni-
tor anti-fXa levels and not to adjust the doses for increasing body-
weight or increasing renal clearance.
The women who received their last injection of LMWH within 24
hours before delivery had no increased bleeding risk compared to
women who delivered after 24 hours. The ACCP guidelines recom-
mend a weight-adjust twice-daily dosage LMWH and discontinuation
of LMWH at least 24 hours prior to elective induction of labor (Grade
1 C).[6] In our hospital women who use anticoagulation for (preven-
tion of) VTE have no standard planned induction of labor, but allwomen switched to divided therapeutic weight-adjusted dosing of
LMWH in the 37th week to minimize the bleeding risk. However, di-
viding the LMWH dose into twice daily doses and stopping at start of
labor may decrease the anticoagulant effect at delivery. In total, only
30% of the women in our cohort had a planned labor. The incidence
of PPH in the women who had a spontaneous labor seems to be
higher compared to women with a planned labor, (OR 1.9; 95% CI
0.6-5.8; p=0.29) but not reaching statistical signiﬁcance. This differ-
ence cannot be explained by a longer duration between delivery and
the last dose of LMWH, because the number of women who delivered
within 24 hours was comparable in both groups. Reassuringly, in
women who delivered within 12 hours after last dose of LMWH, no
severe PPH occurred and no woman needed a RBC transfusion. One
study by Maslovitz et al.[8] described the bleeding risk postpartum
related to the timing of last injection of LMWH. They found no in-
creased bleeding risk in the women who delivered within 24 hours,
but most of these patients (84%) had only a prophylactic dosage of
enoxaparin.
Our study has some limitations. Firstly, the amount of blood loss
was not objectively measured, but as in common clinical practice
the blood loss was a visual estimation. It is known that this gives
mostly an underestimation of the amount of blood loss[23–25], in
particular a higher estimated blood loss (>500 ml) is associated
with a greater underestimation.[26] In our cohort we observed an in-
creased risk for a >500 ml blood loss in vaginal delivery but no in-
creased risk for >1000 ml. The latter could be explained by visual
underestimation of especially the higher amounts of blood loss.
Secondly, the obstetricians attending the birth were not blinded
and may have managed the third stage of labour differently in an
anticoagulated patient either by administering prophylactic agents
(i.e. oxytocics) or intervening earlier to prevent PPH. However, all
women (users and non-users) who deliver in our hospital have an ac-
tive management of the third stage of labor, including oxytocin.
Thirdly, we did not evaluate the therapeutic anticoagulant effect
with objective laboratory analyses. Therefore, it may be possible
that a proportion of patients did not reach therapeutic levels of
LMWH in the third trimester. Finally, the collecting of data about
the delivery and timing of last dose of LMWH retrospectively is a lim-
itation. Consequently, we had 17% missing data about the timing and
two womenwith missing data had a PPH. However, the median blood
loss of these women was comparable with the women without miss-
ing data.
Given the increased risk of PPH for vaginal and emergency CS de-
livery in women using full dose LMWH for prevention of VTE during
pregnancy, the individual risk of VTE and PPH should be balanced.
We will reconsider our treatment protocol, maybe in a subgroup of
patients a prophylactic dose of anticoagulation during pregnancy
might result in more net beneﬁt.[27] A randomized trial comparing
full dose LMWH with prophylactic dose LMWH in pregnant women
with an increased risk of VTE is needed to improve patient care.
In conclusion, high dose LMWH carries an increased risk of PPH
after vaginal delivery. However, it does not lead to an increased
risk for a severe and clinical relevant PPH. It is unknown whether
this risk is offset by a lower risk of (recurrent) VTE. Secondly,
PPH risk seems to not be increased after deliveries within 24
hours after the last injection of LMWH compared to women who
delivered after 24 hours.
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